SPECTAMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SPECTAMINE (SPECTAMINE).
SPECTAMINE (iofetamine I-123) is a radiopharmaceutical that crosses the blood-brain barrier and localizes in the brain proportional to regional cerebral blood flow. It binds to striatal dopamine transporters (DAT) and is used as a marker for dopamine transporter density.
| Metabolism | Iofetamine I-123 is metabolized in the liver to p-iodoamphetamine and other metabolites. The primary route of excretion is renal. |
| Excretion | Renal: >90% as unchanged drug within 24 hours; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 13-17 hours; clinically, effective half-life for brain SPECT imaging is 6-9 hours due to redistribution. |
| Protein binding | Approximately 75% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: 6-8 L/kg, indicating extensive tissue distribution, particularly in brain and liver. |
| Bioavailability | IV: 100% (only route of administration). |
| Onset of Action | IV: 30-60 minutes for detectable brain uptake; peak activity at 2-4 hours. |
| Duration of Action | Adequate imaging window: 4-6 hours post-injection; significant washout by 24 hours. |
SPECTAMINE (technetium Tc-99m exametazime) is administered intravenously. For brain imaging, the recommended adult dose is 10-20 mCi (370-740 MBq). For white blood cell labeling, the dose is 10-20 mCi (370-740 MBq) after labeling autologous leukocytes.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines are provided for renal impairment. As technetium Tc-99m exametazime is eliminated primarily via the kidneys, caution is advised in patients with severe renal impairment. Use lowest effective dose. |
| Liver impairment | No specific dose adjustment guidelines for hepatic impairment. Caution in severe hepatic impairment due to potential altered clearance. |
| Pediatric use | Dosing in pediatric patients is based on body weight and the specific procedure. For brain imaging, the dose is 0.20 mCi/kg (7.4 MBq/kg) with a minimum dose of 1 mCi (37 MBq). For white blood cell labeling, the dose is 0.20 mCi/kg (7.4 MBq/kg) using labeled cells. |
| Geriatric use | No specific dose adjustments for geriatric patients. Standard adult dosing applies; consider lower end of dose range due to potential age-related decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SPECTAMINE (SPECTAMINE).
| Breastfeeding | Iodine-123 is excreted in human breast milk. The estimated M/P ratio is approximately 10. Breastfeeding should be interrupted for at least 24 hours (or longer based on local guidelines) after administration to minimize infant radiation exposure. Milk should be pumped and discarded during this period. |
| Teratogenic Risk | SPECTAMINE (Iofetamine I-123) is a radiopharmaceutical. The radioactive iodine-123 component can cross the placenta and accumulate in fetal tissues, particularly the thyroid, with potential for fetal thyroid damage and carcinogenesis. Use is contraindicated in pregnancy unless benefit clearly outweighs risk. No adequate human studies exist; animal studies have not been performed. Trimester-specific risks: highest risk in first trimester for teratogenesis; second and third trimesters risk of fetal thyroid ablation. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to iofetamine or any component of the formulation."]
| Precautions | ["Hypersensitivity reactions including anaphylaxis may occur.","Seizures have been reported in patients with a history of seizure disorders or those taking medications that lower seizure threshold.","Image interpretation may be affected by patient motion, recent neuroleptic use, or other conditions affecting dopamine transporter binding.","Ensure adequate hydration to minimize radiation exposure to the bladder.","Use with caution in patients with hepatic or renal impairment."] |
Loading safety data…
| Fetal Monitoring | Prior to administration, confirm pregnancy status in women of childbearing potential. No specific fetal monitoring required if used in pregnancy after careful risk-benefit assessment. Post-administration, monitor for maternal adverse reactions (e.g., allergic reactions). |
| Fertility Effects | Potential for radiation-induced gonadal damage with possible reduction in fertility. Reversible effects on spermatogenesis and oogenesis may occur with high cumulative doses. Use caution in individuals planning pregnancy. |